Atlas Trials

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

Clinical trial NCT03325881 · COMPLETED

Trial details

NCT number
NCT03325881
Sponsor
Shire
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Attention Deficit Hyperactivity Disorder (ADHD)
Start date
2017-12-09
Primary completion
2018-06-07
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.